CNSP (CNS Pharmaceuticals) EBITDA Margin %: 0.00% (As of Mar. 2026)


CNSP CNS Pharmaceuticals Inc CNSP
30 GF Score
Price $3.98
! 1 Warning Sign
View Full Analysis

What is CNS Pharmaceuticals EBITDA Margin %?

CNS Pharmaceuticals CNSP -4.14% 30 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates CNSP with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, CNS Pharmaceuticals ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. CNS Pharmaceuticals's EBITDA for the three months ended in Mar. 2026 was $-4.93 Mil. CNS Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, CNS Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

CNS Pharmaceuticals  (NAS:CNSP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

CNS Pharmaceuticals EBITDA Margin % Related Terms

CNS Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for CNS Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals EBITDA Margin % Chart

CNS Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNS Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNSP vs SYBX, ELAB, GNPX: EBITDA Margin % Comparison

For the Biotechnology subindustry, CNS Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNS Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNS Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where CNS Pharmaceuticals's EBITDA Margin % falls into.


CNSP
30GF Score
CNS Pharmaceuticals Inc CNSP
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CNS Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

CNS Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-15.831/0
= %

CNS Pharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.929/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
CNS Pharmaceuticals (CNSP) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CNS Pharmaceuticals and its competitors. According to the industry distribution chart, CNS Pharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry.
Is CNS Pharmaceuticals' EBITDA Margin % too high?
CNS Pharmaceuticals' current EBITDA Margin % is 0.00%. Based on the distribution chart, CNS Pharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CNS Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CNS Pharmaceuticals' EBITDA Margin % compare to SYBX and ELAB?
According to the Biotechnology industry distribution chart, CNS Pharmaceuticals ranks #999999 out of 944 companies for EBITDA Margin %. This places CNS Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CNS Pharmaceuticals and its competitors. CNS Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNS Pharmaceuticals stock overvalued right now?
CNS Pharmaceuticals (CNSP) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. CNS Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CNS Pharmaceuticals (CNSP), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNS Pharmaceuticals Business Description

Address 2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
30GF Score

Get the complete analysis for CNSP

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.98
Price